Return on Equity (ROE) is 13.7. It is considered poor, since it is below 15%Gross Profit Margin (GPM) is 66.3. It is considered good, since it is above 20%Operating Profit Margin (OPM) is 25.9. It is considered good, since it is above 15%Net Profit Margin (NPM) is 25.9. It is considered good, since it is above 10%Price to Earnings Growth (PEG) ratio is 3.82. It is considered under valued, since it is PEG is below 5EPS follows M (fluctuating) pattern. EPS value of the company is increasing and decreasing for every alternate quater respectively. In the last quater the EPS is decreasing. Zydus Lifesciences Ltd's EPS is lower than its peers.Net Profit follows W (fluctuating) pattern. Net Profit value of the company is decreasing and increasing for every alternate quater respectively. In the last quater the Net Profit is decreasing.EBIT follows M (fluctuating) pattern. EBIT value of the company is increasing and decreasing for every alternate quater respectively. In the last quater the EBIT is decreasing. Zydus Lifesciences Ltd's EPS is greater than its peers.Revenue follows M (fluctuating) pattern. Revenue value of the company is increasing and decreasing for every alternate quater respectively. In the last quater the Revenue is decreasing.The Debt-To-Equity is 0.01. As it is lower than 0.5. It is considered low or conservative.The Interest coverage ratio is 49.3. As the value is more than 1.75. It is considered good.The working capital turnover ratio of 3.268. As the value is more than 2. It is considered really good.The Asset turnover is 0.65. As the value is less than 1, it is considered poor.Cash from investing activity follows M (fluctuating) pattern. Cash from investing activity value of the company is increasing and decreasing for every alternate year respectively. In the last year the Cash from investing activity is increasing.Cash from operating activity follows M (fluctuating) pattern. Cash from operating activity value of the company is increasing and decreasing for every alternate year respectively. In the last year the Cash from operating activity is increasing.Cash from financing activity follows M (fluctuating) pattern. Cash from financing activity value of the company is increasing and decreasing for every alternate year respectively. In the last year the Cash from financing activity is decreasing. Zydus Lifesciences Ltd's total assets is greater than its peers.The PE Ratio is 23.8 Since the PE_Ratio is above 20, the stock is Over valuedThe Price to Book Ratio is 3.98 Since the price to Book Ratio is over 1 the stock is Over valuedThe Price to Sales Ratio is 3.97 Since the Price to Sales ratio is more than 1.8, the stock is OvervaluedThe Dividend yield is 0.81 Since the Dividend Yield is less than 1.0 the stock is UndervaluedThe ROCE is 15.0 Since the ROCE is between 10 and 15 it is the Industry AverageThe EV/EBITDA is 14.7 Since the EV/EBITDA ratio is more than 3.0 the stock is OvervaluedThe EV/EBITDA is 14.7 Since the EV/EBITDA ratio is more than 3.0 the stock is OvervaluedThe Quick Ratio is 1.52 Since the Quick Ratio is more than 1, the stock is Financially HealthyThe Current Ratio is 2.28 Since the Current Ratio is more than 2.0 the stock is Financially Healthy